Skip to main content
CBUS
NASDAQ Industrial Applications And Services

Cibus Q2 2026: Net Loss Narrows 43%, Cash Runway Extended to Early Q1 2027

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$1.616
Mkt Cap
$145.03M
52W Low
$1.09
52W High
$4.191
52W Position info
48% above low
Off High info
61% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

CBUS sits 48% above its 52-week low of $1.09.

Summary

Cibus cut its net loss by 43% year-over-year and extended its cash runway into early Q1 2027, but the going concern warning persists. The 10-Q details recent capital raises and an expanded Rice partnership with Interoc.


Key Events · Earnings and Guidance · CBUS

  • Net Loss Narrows 43%

    Net loss attributable to Cibus stockholders was $43.4 million for H1 2026, down from $72.3 million in H1 2025, driven by a 28% cut in R&D and a 36% cut in SG&A.

  • Cash Runway Extended to Early Q1 2027

    Cash and equivalents stood at $20.4 million as of June 30, 2026. Management expects this to fund operations into early Q1 2027, but the going concern warning remains — additional capital is required.

  • Recent Financings Detailed

    January 2026 offering: 14.8M shares at $1.50 for $19.8M net. March 2026 offering: 7.0M shares at $2.15 for $13.6M net. A $50M ATM facility with Jefferies was established May 15, 2026; only 3,059 shares issued so far.

  • Rice Partnership Expanded

    The Interoc letter of intent was amended in August 2026 to expand from two to five Rice traits. Initial launch in Latin America is now targeted for 2028, with US expansion in 2029.


Analysis · CBUS · Industrial Applications And Services

Cibus reported a significantly narrower net loss of $43.4 million for the first half of 2026, down from $75.9 million a year earlier, driven by aggressive cost cutting. The company extended its cash runway into early Q1 2027, but the going concern warning remains — it needs to raise more capital. The 10-Q also reveals the full terms of recent financings: $19.8 million net from a January offering at $1.50/share and $13.6 million net from a March offering at $2.15/share, plus a $50 million ATM facility with Jefferies. The Rice program expanded its Interoc partnership from two to five traits, and the company pushed its Latin America launch to 2028. This is a critical update for a pre-revenue biotech with a $145 million market cap and a going concern flag.

At the time of this filing, CBUS was trading at $1.62 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $145M. The 52-week trading range was $1.09 to $4.19. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CBUS - Latest Insights

CBUS
Aug 13, 2026, 4:14 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.68
Real-time Price: $1.60 info
Change: -$0.0792 (-5%) info
Market Cap: $145.03M info
CBUS
Jun 17, 2026, 8:05 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $1.32
Real-time Price: $1.60 info
Change: +$0.2808 (+21%) info
Market Cap: $145.03M info
CBUS
Jun 09, 2026, 8:19 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.23
Real-time Price: $1.60 info
Change: +$0.3708 (+30%) info
Market Cap: $145.03M info
CBUS
May 22, 2026, 4:59 PM EDT
Filing Type: 424B3
Importance Score:
7
Price at Filing: $1.35
Real-time Price: $1.60 info
Change: +$0.2508 (+19%) info
Market Cap: $145.03M info
CBUS
May 15, 2026, 4:47 PM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $1.32
Real-time Price: $1.60 info
Change: +$0.2804 (+21%) info
Market Cap: $145.03M info